DENALI THERAPEUTICS INC (DNLI) competitors & alternatives
Health Care · NASDAQ
DENALI THERAPEUTICS INC (DNLI)'s top competitors and alternatives — its most similar public companies — include Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY), SPRUCE BIOSCIENCES INC (SPRB), PROTHENA PLC (PRTA), MEIRAGTX HOLDINGS PLC (MGTX), SUPERNUS PHARMACEUTICALS INC (SUPN), ZEVRA THERAPEUTICS INC (ZVRA), PTC THERAPEUTICS INC (PTCT), AMYLYX PHARMACEUTICALS INC (AMLX), PRECISION BIOSCIENCES INC (DTIL), PROTALIX BIOTHERAPEUTICS INC (PLX) and ANAVEX LIFE SCIENCES CORP (AVXL). These are DENALI THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top DNLI competitors & alternatives
-
Ionis PharmaceuticalsIONSHealth Care
Pioneer in RNA-targeted antisense medicines with seven commercialized products and expanding late-stage pipeline across rare neurological and cardiometabolic…
$54.01 (as of 2026-07-22) · market cap $8.8B
-
Alnylam PharmaceuticalsALNYHealth Care
Alnylam is a global leader in RNA interference therapeutics, pioneering a new class of genetic medicines to treat rare and serious diseases.
$266.99 (as of 2026-07-22) · market cap $36.2B
-
SPRUCE BIOSCIENCES INCSPRBHealth Care
Clinical-stage biopharmaceutical company developing tralesinidase alfa enzyme replacement therapy for rare lysosomal storage disorders, particularly Sanfilippo…
$44.60 (as of 2026-07-22) · market cap $123M
-
PROTHENA PLCPRTAHealth Care
A clinical-stage biotech developing antibody therapies targeting misfolded proteins in Parkinson's disease, Alzheimer's disease, and rare amyloidosis through…
$8.44 (as of 2026-07-22) · market cap $458M
-
MEIRAGTX HOLDINGS PLCMGTXHealth Care
A vertically integrated clinical-stage genetic medicines company developing locally-delivered gene therapies for ophthalmology, Parkinson's disease, and…
$12.16 (as of 2026-07-22) · market cap $1.1B
-
SUPERNUS PHARMACEUTICALS INCSUPNHealth Care
Supernus is a biopharmaceutical company commercializing approved CNS treatments across ADHD, Parkinson's disease, postpartum depression, epilepsy, and migraine…
$46.94 (as of 2026-07-22) · market cap $2.8B
-
ZEVRA THERAPEUTICS INCZVRAHealth Care
Zevra brings life-changing therapies to ultra-rare neurodegenerative and metabolic diseases, with FDA-approved MIPLYFFA for Niemann-Pick disease type C now…
$12.14 (as of 2026-07-22) · market cap $762M
-
PTC THERAPEUTICS INCPTCTHealth Care
PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved…
$78.40 (as of 2026-07-22) · market cap $6.5B
-
AMYLYX PHARMACEUTICALS INCAMLXHealth Care
Clinical-stage biotech developing novel therapies for endocrine and neurodegenerative disorders, with a lead GLP-1 receptor antagonist for post-bariatric…
$17.70 (as of 2026-07-22) · market cap $2.0B
-
PRECISION BIOSCIENCES INCDTILHealth Care
Precision BioSciences is a clinical-stage biotechnology company leveraging its proprietary ARCUS gene editing platform to develop potentially curative in vivo…
$7.32 (as of 2026-07-22) · market cap $189M
-
PROTALIX BIOTHERAPEUTICS INCPLXHealth Care
A rare-disease biopharmaceutical company with a proprietary plant cell-based protein expression platform and two FDA/EMA-approved enzyme replacement therapies…
$2.37 (as of 2026-07-22) · market cap $190M
-
ANAVEX LIFE SCIENCES CORPAVXLHealth Care
Anavex is a clinical-stage biotech developing sigma-1 receptor agonists for neurodegenerative and rare CNS disorders, with lead program ANAVEX 2-73 in multiple…
$2.55 (as of 2026-07-22) · market cap $234M
Not quite? Describe exactly what you want →
Peers are DENALI THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: DENALI THERAPEUTICS INC (DNLI).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.